Cargando…
What should we expect when two myositis-specific antibodies coexist in a patient
BACKGROUND: The coexistence of two myositis-specific autoantibodies (MSA) is considered extremely rare. We describe three patients with both anti-signal recognition particle (SRP) antibodies and another MSA in serum. METHODS: We performed a retrospective clinical data collection and follow-up studie...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571367/ https://www.ncbi.nlm.nih.gov/pubmed/37828570 http://dx.doi.org/10.1186/s40001-023-01363-5 |
_version_ | 1785119974636912640 |
---|---|
author | Zheng, Yiming Zhao, Yawen Hao, Hongjun Wang, Zhaoxia Gao, Feng Zhang, Wei Yuan, Yun |
author_facet | Zheng, Yiming Zhao, Yawen Hao, Hongjun Wang, Zhaoxia Gao, Feng Zhang, Wei Yuan, Yun |
author_sort | Zheng, Yiming |
collection | PubMed |
description | BACKGROUND: The coexistence of two myositis-specific autoantibodies (MSA) is considered extremely rare. We describe three patients with both anti-signal recognition particle (SRP) antibodies and another MSA in serum. METHODS: We performed a retrospective clinical data collection and follow-up studies of the clinical manifestations and treatment outcome of three patients positive with anti-SRP antibodies and other MSAs. IgG antibodies against MSAs were detected using commercial line immunoblot assay. RESULTS: The tests of MSA showed positive result of anti-SRP antibodies and another one MSA including anti-TIF1-γ, anti-Jo1, or anti-EJ antibodies, respectively. The proximal muscle weakness appeared in 2 patients; interstitial lung disease presented in 2 patients. The serum CK level was elevated in 1 patient. The muscle biopsy showed necrotizing myopathy in 1 patient and deposition of membrane attack complex on scattered myofibers in the other one patient. One of the two patients with interstitial lung disease died because of respiratory failure. One patient had completely improved and the other one showed partial remission after immunosuppressive therapy. CONCLUSIONS: The patients with anti-SRP antibodies co-occurred with the other MSA may have various clinical characteristics. The clinicopathological phenotypes of these patients seem to be mainly caused by one of the MSAs, namely the responsible antibody. |
format | Online Article Text |
id | pubmed-10571367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105713672023-10-14 What should we expect when two myositis-specific antibodies coexist in a patient Zheng, Yiming Zhao, Yawen Hao, Hongjun Wang, Zhaoxia Gao, Feng Zhang, Wei Yuan, Yun Eur J Med Res Research BACKGROUND: The coexistence of two myositis-specific autoantibodies (MSA) is considered extremely rare. We describe three patients with both anti-signal recognition particle (SRP) antibodies and another MSA in serum. METHODS: We performed a retrospective clinical data collection and follow-up studies of the clinical manifestations and treatment outcome of three patients positive with anti-SRP antibodies and other MSAs. IgG antibodies against MSAs were detected using commercial line immunoblot assay. RESULTS: The tests of MSA showed positive result of anti-SRP antibodies and another one MSA including anti-TIF1-γ, anti-Jo1, or anti-EJ antibodies, respectively. The proximal muscle weakness appeared in 2 patients; interstitial lung disease presented in 2 patients. The serum CK level was elevated in 1 patient. The muscle biopsy showed necrotizing myopathy in 1 patient and deposition of membrane attack complex on scattered myofibers in the other one patient. One of the two patients with interstitial lung disease died because of respiratory failure. One patient had completely improved and the other one showed partial remission after immunosuppressive therapy. CONCLUSIONS: The patients with anti-SRP antibodies co-occurred with the other MSA may have various clinical characteristics. The clinicopathological phenotypes of these patients seem to be mainly caused by one of the MSAs, namely the responsible antibody. BioMed Central 2023-10-12 /pmc/articles/PMC10571367/ /pubmed/37828570 http://dx.doi.org/10.1186/s40001-023-01363-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zheng, Yiming Zhao, Yawen Hao, Hongjun Wang, Zhaoxia Gao, Feng Zhang, Wei Yuan, Yun What should we expect when two myositis-specific antibodies coexist in a patient |
title | What should we expect when two myositis-specific antibodies coexist in a patient |
title_full | What should we expect when two myositis-specific antibodies coexist in a patient |
title_fullStr | What should we expect when two myositis-specific antibodies coexist in a patient |
title_full_unstemmed | What should we expect when two myositis-specific antibodies coexist in a patient |
title_short | What should we expect when two myositis-specific antibodies coexist in a patient |
title_sort | what should we expect when two myositis-specific antibodies coexist in a patient |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571367/ https://www.ncbi.nlm.nih.gov/pubmed/37828570 http://dx.doi.org/10.1186/s40001-023-01363-5 |
work_keys_str_mv | AT zhengyiming whatshouldweexpectwhentwomyositisspecificantibodiescoexistinapatient AT zhaoyawen whatshouldweexpectwhentwomyositisspecificantibodiescoexistinapatient AT haohongjun whatshouldweexpectwhentwomyositisspecificantibodiescoexistinapatient AT wangzhaoxia whatshouldweexpectwhentwomyositisspecificantibodiescoexistinapatient AT gaofeng whatshouldweexpectwhentwomyositisspecificantibodiescoexistinapatient AT zhangwei whatshouldweexpectwhentwomyositisspecificantibodiescoexistinapatient AT yuanyun whatshouldweexpectwhentwomyositisspecificantibodiescoexistinapatient |